A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
A phase 2 trial of JNJ-90301900, Durvalumab and Carboplatin in non-small-cell lung cancer, run by Johnson & Johnson Enterprise Innovation Inc., now recruiting.
Overview
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06667908 by Johnson & Johnson Enterprise Innovation Inc., with 130 participants planned, started 2024-12-06 and due to reach its primary completion in 2028-12-31. Interventions recorded: JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin and Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel.
Similar pages
not linked directly; found by shared links- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Durvalumab, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Durvalumab, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Durvalumab, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialDurvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Shares Durvalumab, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Durvalumab, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Shares Durvalumab, Carboplatin, Non-small-cell lung cancer and the tag pipeline.